BioLASCO Taiwan Co (6662) Fair Value & Analysis
Healthcare · TW · Market cap 779M TWD
Fair value as of: Jul 23, 2026
From 24 valuation models · updated 18 days ago
Share price −2.0% over the past month.
A solid business, but screening 27% overvalued on our models.
What matters now
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (15.27 TWD to 29.54 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 23.93 TWD – 37.08 TWD · fair‑value band 15.27 TWD – 29.54 TWD · the 28.80 TWD price screens above the 20.99 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
BioLASCO Taiwan Co (6662) currently trades at 28.80 TWD, while our model-based Fair Value estimate is 20.99 TWD, implying the stock looks roughly 27.1% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, BioLASCO Taiwan Co generated revenue of 263M TWD at a net margin of 16.2%. Revenue declined 17.3% year over year. It earns a return on equity of 9.4%. Net debt stands at 10.8M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 15.27 TWD (bear case) to 29.54 TWD (bull case); at 28.80 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -27%, 6662 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (28.16 TWD) versus Growth DCF (11.76 TWD). Highest evidence: Growth DCF (80).
Notify me when 6662 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally.
Full company description
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally. The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment. It also offers reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, rapid microbial detection, biological indicators, and iReal antibody; and various services, such as animal testing, pathology and toxicology, serological testing, lab animal center management services. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioLASCO Taiwan Co reported revenue of 263M TWD in FY2025 versus 228M TWD in FY2021, a compound +3.6%/yr. Reported net income was 42.4M TWD in FY2025, compounding −1.5%/yr from FY2021.
6662 screens 27% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare BioLASCO Taiwan Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioLASCO Taiwan Co (6662) overvalued or undervalued?
What is the fair value of 6662?
What is the quality score of 6662?
What is the revenue of BioLASCO Taiwan Co (6662)?
What is the net profit margin of 6662?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BioLASCO Taiwan Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.